<code id='9621B51827'></code><style id='9621B51827'></style>
      • <acronym id='9621B51827'></acronym>
      <center id='9621B51827'><center id='9621B51827'><tfoot id='9621B51827'></tfoot></center><abbr id='9621B51827'><dir id='9621B51827'><tfoot id='9621B51827'></tfoot><noframes id='9621B51827'>
      • <optgroup id='9621B51827'><strike id='9621B51827'><sup id='9621B51827'></sup></strike><code id='9621B51827'></code></optgroup>
        5. <b id='9621B51827'><label id='9621B51827'><select id='9621B51827'><dt id='9621B51827'><span id='9621B51827'></span></dt></select></label></b><u id='9621B51827'></u>
          <i id='9621B51827'><strike id='9621B51827'><tt id='9621B51827'><pre id='9621B51827'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-29 01:49:59 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：knowledge   
                                        
                                      
                                      Page View：59322
                                  
                                    
          
                                   
          Adobe
          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.
          The deal includes up to another $400 million in payments if certain milestones are met.
          advertisement
          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Humana’s Medicare Advantage lawsuit should be tossed, DOJ says
                                
                            
          Next article：  
                                      
                                          Psychedelics group wrestles with new pharma identity
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles